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Introduction. Influenza A H1N1 community-acquired pneumonia (CAP) is a quite frequent respiratory disease. Despite being
considered more serious than other CAPs, there are very few studies comparing its characteristics with noninfluenza CAP. We
aim to establish the differences between pneumonia due to H1N1 virus and pneumonia not caused by H1N1 influenza virus and to
determine the probability that a pneumonia is due to an H1N1 virus infection based on the most relevant variables.Methods. We
used a case-control study where cases were H1N1 CAP patients with confirmed microbiological diagnosis and controls were
patients with CAP admitted to hospital. H1N1 and other influenza types were discarded among controls. We calculated the
probability of being a case or control using multivariate logistic regression. Results. We included 99 cases and 270 controls. Cases
were younger than controls (53 vs 71 years, respectively). Mortality was much higher for H1N1 patients (13% vs 0.3%), and
admission to intensive care unit was more frequent for H1N1 cases. 'e variables most associated with presenting H1N1 CAP
were bilateral affectation on chest X-rays (OR: 5.70; 95% CI 2.69–10.40), followed by presence of arthromyalgias, with cases
presenting close to three times more arthromyalgias compared to controls. Low leukocytes count and high AST values were also
significantly associated with H1N1 CAP. H1N1 CAPs are characterized by bilateral affectation, low leukocyte count, presence of
arthromyalgias, and high AST. Conclusions. A few and easy to obtain clinical parameters might be extremely useful to distinguish
H1N1 CAP from CAPs of other origin.
1. Introduction
In 2010, virus influenza A/H1N1 (H1N1 onwards) was de-
clared a pandemic disease by the World Health Organization,
the first with this condition in over 40 years [1]. Compared to
other influenza types, H1N1 is considered a more life-
threatening disease. At least 5% of patients with H1N1 in-
fection develop community-acquired pneumonia (CAP) [2],
and symptoms such as dyspnea, wheezing, vomit, and di-
arrhoea are associated with H1N1CAP [2]. H1N1 pneumonia
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may present a rapid progression or with a severe respiratory
distress syndrome and is associated with a longer hospital
stay, more admissions at the intensive care unit, and higher
mortality compared to bacterial CAP [3–6]. At the emergency
care department, it is important to distinguish H1N1 CAP
from bacterial CAP. Establishing a diagnosis as soon as
possible is of paramount importance to make an impact on
patients’ survival and also to avoid spreading the disease. To
date, there are no clear criteria to differentiate influenza A
H1N1 CAP from CAP of other aetiologies (mainly bacterial
ones).
'emain objective of the present study is to establish the
differences between pneumonia due to H1N1 virus and
pneumonia not caused by H1N1 influenza virus and to
create a multivariate model allowing to determine the
probability that a pneumonia is due to an H1N1 virus in-
fection at hospital admission.
2. Subjects and Methods
2.1. Design, Setting, and Definitions. We designed a case-
control study performed at a Spanish third-level hospital,
covering a health area comprising approximately 450,000
inhabitants. Recruitment started in 2009 and finished in 2016.
To be included, a patient had to be diagnosed with CAP and
also admitted to hospital, and afterwards, we defined the case
or control status. All participants had to be older than 16 years.
CAP definition followed the guidelines of the Infectious
Diseases Society of America/American 'oracic Society [7].
A case was defined as a patient with a CAP and a
confirmed microbiological diagnosis of H1N1 influenza A.
Diagnosis was performed with real-time reverse-
transcriptase polymerase chain reaction at the microbiol-
ogy service, following recommendations of the centers for
disease control [8] and without a positive culture for other
microorganisms. Samples were obtained with nasopharyn-
geal swabs on admission. Controls were patients diagnosed
with nonvirus influenza (NVI)-CAP, where influenza A
infection was discarded. In order to have a closer bacterial-
like CAP infection among controls, we excluded patients
from the control group with concurrent influenza CAP.
'ere is a protocol enforced at the hospital, which is ap-
plicable to all CAPs to confirm its origin. Following the
protocol, all patients undergo two blood cultures, sputum
culture, and urine antigens for Streptococcus pneumoniae
and Legionella pneumophila, all of them performed on the
first 24 hours upon admission and before antibiotic treat-
ment. Other tests are performed occasionally including
atypical pathogens serology. We did not perform routine
analysis for viruses apart from influenza A, B and respiratory
syncytial virus.
Antibiotic treatment was prescribed when bacterial
pneumonia was diagnosed following recommendations of
Spanish guidelines [9], and osetalmivir (75mg/12 hours,
5 days) if H1N1 Influenza A was suspected. Osetalmivir was
stopped in patients with a negative microbiological test for
influenza A H1N1.
Cases were all those diagnosed during the study period
(therefore consecutive), and controls were selected by a
frequency sampling regarding cases, based on the influenza
epidemic peak to avoid any bias regarding healthcare
pressure or beds availability. 'e rationale for this
frequency-based sampling was to give the same chance of
hospital admission to both cases and controls with in-
dependence on the aetiology of the CAP. For the different
years included in the recruitment period, a proportional
percentage of cases and controls were selected to consider
H1N1 CAP epidemics.
'e study protocol and ethics were approved by the
Santiago-Lugo Ethics Committee (year 2017/052).
2.2. Information Retrieval. We collected information from
the electronic clinical records regarding the following
variables: age at admission, gender, tobacco consump-
tion, body mass index, month of hospitalization, vacci-
nation (influenza and pneumococcus), Charlson index,
scoring of the Pneumonia Severity Index, and CURB65
[10, 11]. We also collected extensive information on
respiratory infection symptoms, admission to the in-
tensive care unit, and length of stay. Information on
biochemical parameters and cell counting was also ob-
tained. Finally, we classified images from unilateral or
bilateral appearance of pneumonia in chest X-ray. We
followed up all patients using the electronical clinical
records to obtain 30-day mortality upon admission (in-
hospital or at home).
2.3. Statistical Analysis. We performed a bivariate analysis
to compare the characteristics of cases and controls. To
compare categorical variables, we used the chi-squared
test, and if the variables were continuous, we used the
median test. Statistical significance was established at a p
value <0.05. Afterwards, we performed a crude and
multivariate logistic regression. In the crude analysis, we
entered the different variables individually to assess the
probability of being a case or control. We also performed a
full multivariate analysis including the following variables:
age (three categories), gender, pneumococcal vaccination
(yes/no), influenza vaccination (yes/no), leukocytes
(≤500/mm3, >500/mm3), aspartate aminotransferase
(AST) (≤24 IU/L, >25 IU/L), arthromyalgias (no, yes), and
radiography result (lobar, bilobar, and bilateral). PSI score
and CURB-65 were not introduced in the multivariate
analysis because they include age and would result in an
overadjustment of results. Results were expressed as odds
ratios with 95% CI, and we used SPSS v22 for the statistical
analysis.
3. Results
Figure 1 shows the flowchart for the inclusion and exclusion
of patients in the case group. 12 patients with H1N1 CAP
were excluded because they did not want to be admitted to
hospital. 62 patients with non-H1N1 influenza A also were
excluded. 'e study included 369 patients admitted to
hospital (99 H1N1 cases and 270 controls with NVI), all
presenting CAP. In 111 patients of the control group (41%),
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a bacterial origin was microbiologically demonstrated. 'e
most frequent infection among controls were Streptococcus
pneumoniae (45 patients; 40.5%), Legionella pneumophila
(11; 10%); Klebsiella pneumoniae (10; 9%), and methicillin-
resistant Staphylococcus aureus (10; 9%). In the cases group,
9 patients (9%) had a bacterial coinfection. Atypical mi-
croorganisms were identified in six more patients (Myco-
plasma pneumoniae (4 patients) and Chlamydia pneumoniae
(2)). Sample characteristics broken down by case or control
status are shown in Table 1. 'ere were no differences on
gender and trimester of admission, which shows that the
matching on season of the year was appropriate. 'e tri-
mester with the highest number of participants included was
the second (45% of all participants), followed by the first
(18.4%), and the year including most participants was 2016
followed by 2009. Cases were appreciably younger than
controls (median age 53 vs 71), and the percentage of never
smokers was quite similar. Controls were more frequently
vaccinated for influenza and pneumococcus compared to
cases, and controls had a slightly worse Charlson index. 'e
years with the highest number of cases (and also controls)
were 2016 (72 cases) and 2009 (20).
Clinical characteristics of cases compared to controls are
shown in Table 2. Hospitalization at an intensive care unit was
six times more frequent for cases, a rate equivalent for me-
chanical ventilation. Length of stay in the intensive care unit
was 5 times longer for cases.When calculating PSI and CURB-
65 scores, it seems that CURB-65 underestimates the severity
of H1N1 patients. 'ere were no relevant differences on PSI
score between cases and controls. Cell count of white series was
much lower in cases (and also for platelets) than for controls.
AST, alanine aminotransferase (ALT), and gamma-
glutamyl transpeptidase (GGT) were higher in cases com-
pared to controls. 'e percentage of patients with arthro-
myalgias was 3 times higher in cases, and bilateral presence
of pneumonia in chest X-rays was 4 times more frequent for
cases. Mortality was also higher in cases compared to
controls. Cases presented a 13% of mortality (all in-hospital
mortality) compared to only 1 death (<1%) in controls
occurring in the following 30 days after admission.
We calculated the probability of being a case or control
based on different variables (Table 3). Four variables showed
a strong association with being diagnosed as a case, which
were low count of leukocytes, high AST value, presence of
arthromyalgias, and bilateral presence of pneumonia. 'e
characteristic most strongly associated with being a case was
the bilateral presence of pneumonia (OR 5.30; 95% CI
2.69–10.40), followed by arthromyalgias close to three times
more frequent in cases compared to controls. 'e remaining
two variables (high AST and low count of leukocytes)
presented ORs higher than 2.
4. Discussion
We have applied multivariate analysis to compare clinical
characteristics of CAP patients with H1N1 influenza A
versus patients with nonvirus influenza CAP, and the
findings are very relevant. First, it is evident that CAP is
much more serious for H1N1 patients, with a higher
mortality and a higher rate of intensive care unit hospi-
talization. Second, it should be quite easy to distinguish
H1N1 CAP at admission if clinicians at emergency care
Patients infected with influenza virus: 816
Influenza A virus pneumonia: 161
Influenza A H1N1 virus pneumonia: 99
Influenza A but not H1N1 virus pneumonia: 62
Excluded: 655
(i) Lost cases: 92
(ii) Infection without pneumonia: 379
(iii) Infection without radiology: 61
(iv) Pneumonia without admission: 12
(v) Nosocomial infection without pneumonia: 28
(vi) Children: 7
(vii) H1N1 and VRS coinfection: 1
(viii) Influenza A and B coinfection: 2
(xi) Influenza B: 73
Figure 1: Flowchart for the inclusion/exclusion of patients in the case group.
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consider some variables which are easily available, mainly
bilateral location of pneumonia and arthromyalgias.
Several studies have described H1N1 CAP characteristics
[3–6, 12–20]. Patients are usually younger with a sudden
onset of symptoms [4], usually fever, cough, dyspnea, and
arthromyalgias (37–46%) [3, 4, 15]. It is frequent that pa-
tients need admission at an intensive care unit requiring
mechanical ventilation [4, 13], and there is a high death rate
[4]. Blood analysis usually shows less than <1,000 lympho-
cytes/mm3 [3, 4], and practically all patients present high
values of lactate dehydrogenase (LDH)> 350U/L4.'e usual
radiological pattern is consolidation (with or without
ground-glass opacity) located in middle or lower fields with
affectation of three or more pulmonary areas [12]. Never-
theless, few studies have compared these characteristics with
those of patients with NVI CAP [19–21].
'e median age of H1N1 cases in the present study is
slightly higher than that published in other case-series
[3, 4, 13, 19, 21, 22], but significantly lower than the on-
set age for nonvirus influenza CAP (p< 0.01). Arthro-
myalgias are three times more frequent in cases compared to
controls but this symptom is scarcely described in other
case-series [19]. Vaccination rates for influenza and pneu-
mococcus were less frequent in cases compared to controls
but the rate of influenza vaccination was similar to other
series (16%) [13]. We could consider that this low rate might
be a risk factor to present H1N1 CAP. Nevertheless, two
studies have shown that patients deceased with this infection
have a significantly higher rate of vaccination compared to
those surviving [15, 18].
'e percentage of patients admitted to the intensive care
unit (41.5%) was in the upper range of available studies
(28–41%) [3, 13, 15, 19], and the same happened with pa-
tients requiring mechanical ventilation (26.4%; range 11–
75%) [4, 5, 13, 15, 18, 19]. Both percentages were signifi-
cantly higher than those observed for the control group (7%
and 4.8%, respectively), showing the seriousness of this
disease. As a consequence, the length of stay at the hospital
and at the intensive care unit was significantly longer for
H1N1 cases. Nevertheless, CURB-65 and PSI scores were
unable to detect such seriousness. CURB-65 score seems to
clearly underestimate clinical severity because 94% of pa-
tients of the case group had a score ≤2 (and 81.1% in the
control group; p< 0.01). PSI score did not show significant
differences on severity between cases and controls (64.7% vs
52.2% classified as I-III class, respectively). Previous studies
have found similar results, showing that perhaps those
scores are not useful to detect severity of H1N1 CAP in-
fections [3, 14, 19, 23, 24].
'e total count of leukocytes and the percentage of
neutrophils were significantly lower for H1N1 CAP, and this
can reflect a mainly bacterial aetiology for the control group
compared to viral aetiology for cases [21]. Median number
of lymphocytes (700/mm3) was aligned with published in-
formation [3, 4, 25] and was significantly lower compared to
NVI CAP (810/mm3; p< 0.01).
Bilateral affectation through chest X-rays was four times
more frequent in cases compared to controls (61.6 vs 14.8%,
respectively; p< 0.01), with less predominance of alveolar
pattern (76.8% vs 87%; p< 0.01) but with higher interstitial
(8.7% vs 0.7%) and patchy appearance (5% vs 1.1%). 'ese
results are similar to previous studies where 71% of patients
with H1N1 CAP (40/56) [12] and 40.4% (19/47) present
bilateral affectation [21] and the alveolar pattern does not
surpass 50% [12, 13, 26]. 'ese findings might be extremely
helpful when differentiating H1N1 CAP versus NVI CAP.
H1N1 CAP mortality was 13%, significantly higher than
that observed for the control group (0.3%; p< 0.01) and
higher than that expected for pneumonias associated with
seasonal influenza (4.4%) [15] or for severe CAP (5%) [27]. A
high mortality rate is observed in most case-series, with a
range between 7.8% and 18.7% [5, 14, 15, 21, 28], with some
exception [19]. Low mortality for CAP has been associated
with factors such as age lower than 65, lower score on risk
scores, and lack of some factors associated with higher
mortality. 'ese factors are being male, thoracic pain, hy-
pothermia, systolic hypotension, tachypnea, diabetes, neu-
rologic disease, cancer, leukopenia, and multilobar
infiltration [4, 13, 15, 29]. We have observed that the
presence of these factors in our sample is low (data not
Table 1: Comparison of sociodemographic characteristics of cases
and controls.
Variable H1N1 cases(n, %)
Controls
(n, %) p value
Gender
0.18Men 52 (52.5) 163 (60.4)
Women 47 (47.5) 107 (39.6)
Age (years)
<0.01Median 53 71
Percentile 25–75 44–69 57–82
Tobacco use∗
<0.01
Never smoker 43 (43.4) 116 (47.5)
Former smoker 22 (22.2) 80 (32.8)
Smoker 22 (22.2) 48 (19.7)
Unknown 12 (12.2) 0 (0)
Influenza vaccine∗∗
<0.01No 80 (80.8) 156 (60.7)
Yes 18 (18.2) 101 (39.3)
Pneumococcal vaccine
<0.01No 92 (92.3) 213 (83.2)
Yes 7 (7.7) 43 (16.8)
Charlson
0.03Median 0 1
Percentile 25–75 0–2 0–2
CURB65
<0.01
0 27 (27.3) 43 (15.9)
1 40 (40.4) 61 (22.6)
2 26 (26.3) 115 (42.6)
3 5 (5.1) 46 (17.0)
4 0 (0) 5 (1.9)
5 1 (1.0) 0 (0)
PSI score
0.08
1 18 (18.2) 29 (10.7)
2 21 (21.2) 38 (14.1)
3 25 (25.3) 74 (27.4)
4 26 (26.2) 99 (36.7)
5 9 (9.1) 30 (11.1)
∗26 controls had missing information on tobacco use. ∗∗13 controls and 1
case had missing information on influenza vaccine.
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shown), and therefore, this fact might explain the low
mortality observed among controls. Furthermore, to avoid
selection bias, we selected controls at the same time as cases
were recruited to keep the same probability of hospital or
even ICU admissions for both cases and controls. Having
died at hospital was not a cause for excluding cases or
controls.
In a study performed to know the risk factors of H1N1
CAP and their impact on mortality, Reyes et al. obtained
results very similar to ours. Age <60, bilateral infiltrates in
thorax radiography, leucopenia, and low-values of C-re-
active protein (CRP) were predictive of H1N1 CAP [21]. In
our study, CRP was only determined in 43 cases and 144
controls, with a median value of 5.7 and 10.7mg/dL, re-
spectively (p< 0.01).
Differences in vaccination rates are not valuable in this
study since vaccinations in Spain is directed at population
older than 60 or 65, so that these data should only be
compared for age-matched patients to disclose what the
effect of vaccination could be.
'e present research has some advantages. Data are
recorded in electronic clinical records, and H1N1 influenza
A CAP has been confirmed in all cases. We have also col-
lected a high number of covariates, some of them for the first
time regarding H1N1 influenza A. On the other hand,
having included all consecutive cases of H1N1 CAP in-
fluenza between 2009 and 2016 guarantees the lack of se-
lection bias. We were able to confirm bacterial origin in 41%
of patients from the control group but this percentage is
probably higher because it is not always possible to identify
Table 2: Factors related with hospitalization and mortality.
Variable H1N1 cases (n, %) Controls (n, %) p value
Admission to the intensive care unit
<0.01No 58 (58.5) 251 (93.0)
Yes 41 (41.5) 19 (7.0)
Length of stay at intensive care unit (days)∗
<0.01Median 14 3
Percentile 25–75 8–24.5 2–7
Needed invasive ventilation
<0.01No 63 (63.6) 256 (95.2)
Yes 36 (26.4) 13 (4.8)
Length of hospital stay (days)
<0.01Median 10 7
Percentile 25–75 7–19 5–9
In-hospital mortality 13 (13) 0 (0) <0.01
Mortality following hospital discharge (<30 days) 0 (0) 1 (0.3) <0.01
Leukocytes (cell/mm3)
<0.01Median 6,560 12,250
Percentile 25–75 4,230–9,540 8,077–18,577
Neutrophils (cell/mm3)
<0.01Median 5,300 9,900
Percentile 25–75 6,307.5–15,685 2,910–7,980
Lymphocytes (cell/mm3)
<0.01Median 700 810
Percentile 25–75 430–1,200 600–1,267.5
Monocytes (cell/mm3)
<0.01Median 300 590
Percentile 25–75 110–540 380–800
AST (IU/L)
<0.01Median 45 21
Percentile 25–75 24.5–103.5 15–37
Arthromyalgia
<0.01No 62 (62.6) 235 (87.3)
Yes 37 (37.4) 34 (12.7)
Chest X-ray presentation
<0.01Lobar 37 (37.4) 205 (75.9)Bilobar 1 (1.0) 25 (9.3)
Bilateral 61 (61.6) 40 (14.8)
Radiological pattern
<0.01
Alveolar 76 (76.8) 235 (87.0)
Interstitial 8 (8.1) 2 (0.7)
Alveolointerstitial 10 (10.1) 30 (11.1)
Patchy radiological involvement 5 (5.0) 3 (1.1)
ALT: alanine aminotransferase; AST: aspartate aminotransferase; CURB65: pneumonia severity score calculator 65; GGT: gamma-glutamyl transpeptidase;
PSI score: pneumonia severity index score; pO2: O2 partial pressure. ∗Obtained for cases admitted at ICU.
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the bacterial origin in all pneumonias [7] and because pa-
tients with other influenza types (with a positive identifi-
cation) were excluded. Finally, the multivariate logistic
regression included 8 variables, allowing statistical adjust-
ment for many potential confounders.
'is research has some limitations. It is a retrospective
study, and the sample size is not very high, particularly the
number of cases. Nevertheless, comparing the number of
cases included with other published studies on H1N1 CAP,
the present study has one of the highest number of influenza
A H1N1 confirmed cases. A further limitation is that, for
some variables such as LDH and CRP, we did not have
information from all participants to be included in the
multivariate analysis.
To conclude, H1N1 CAP presents a specific pattern
which might facilitate an a priori easy identification at the
emergency care department. 'is pattern is characterized by
bilateral affectation (in chest X-ray image), low leukocyte
count, presence of arthromyalgias, and high AST. Com-
monly used risk scores to predict community-acquired
pneumonia severities such as CURB-65 or PSI seem to
underestimate H1N1 CAP severity.
Data Availability
'e data used to support the findings of this study are
available from the corresponding author upon request.
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